120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
Eravacycline、替加环素和奥马环素对碳青霉烯耐药鲍曼不动杆菌和肺炎克雷伯菌的体外活性及临床结局比较
Authors Chen D, Lan H, Yang W, Tian D, Liu Y, Ju L , Song Q, Min R , Wang Y, Li Y, Wang P, Cao J
Received 27 November 2025
Accepted for publication 5 February 2026
Published 13 February 2026 Volume 2026:19 583973
DOI https://doi.org/10.2147/IDR.S583973
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Hazrat Bilal
Diandian Chen,1,* He Lan,1,* Wenshuo Yang,1,* Dequan Tian,1 Yunyi Liu,1 Leyang Ju,1 Qiao Song,1 Rong Min,1 Yan Wang,1 Ying Li,1 Peichang Wang,1,2 Jingrong Cao1,2
1Department of Clinical Laboratory, Xuanwu Hospital Capital Medical University, National Gerontic Disease Clinical Research Center, Beijing, 100053, People’s Republic of China; 2Department of Clinical Laboratory, Xiong’an Xuanwu Hospital, Xiong’an New Area, Hebei Province, 070001, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jingrong Cao, Department of Clinical Laboratory, Xuanwu Hospital Capital Medical University, National Gerontic Disease Clinical Research Center, No. 45 Changchun Street, Xicheng District, Beijing, 100053, People’s Republic of China, Email 13683581168@126.com Peichang Wang, Department of Clinical Laboratory, Xuanwu Hospital Capital Medical University, National Gerontic Disease Clinical Research Center, No. 45 Changchun Street, Xicheng District, Beijing, 100053, People’s Republic of China, Email pcw1905@126.com
Purpose: Carbapenem-resistant Acinetobacter baumannii (CRAB) and Klebsiella pneumoniae (CRKP) pose a serious public health threat, underscoring the urgent need for novel therapeutic options. This study compared the in vitro antimicrobial activity and associated clinical outcomes of three tetracycline-class antibiotics—eravacycline (ERV), tigecycline (TGC), and omadacycline (OMC)—against regional carbapenem-resistant isolates.
Patients and Methods: A total of 106 CRKP and 117 CRAB non-duplicate clinical isolates were collected from Xuanwu Hospital (Beijing) between December 2024 and June 2025. Minimum inhibitory concentrations (MICs) were determined using broth microdilution (CLSI M07 guidelines). Time-kill assays (0– 48 h) were used to evaluate bactericidal activity, and clinical outcomes were analyzed in patients treated with TGC or ERV.
Results: ERV demonstrated superior in vitro activity: its MIC90 against CRKP (0.5 μg/mL) was 4-fold lower than TGC (2 μg/mL) and 8-fold lower than OMC (4 μg/mL). For CRAB, ERV’s MIC90 (0.25 μg/mL) was 4-fold lower than TGC (1 μg/mL). ERV maintained sustained bactericidal activity (≥ 3-log10 CFU/mL reduction) for 24– 36 h against CRAB— 2.3-fold longer than TGC and 3.1-fold longer than OMC. ERV-treated patients (n = 20) showed a 5% mortality rate (6.7% for CRAB and 0% for CRKP), compared with 18.9% (CRAB) and 16.7% (CRKP) in TGC-treated patients.
Conclusion: Current evidence indicates that ERV exhibits strong in vitro bactericidal activity and demonstrates more favorable clinical efficacy comparable to that of TGC against CRKP and CRAB infections, as observed in our retrospective clinical cohort.
Plain Language Summary: Faced with the increasing threat of CRAB and CRKP, this study evaluated effectiveness of three tetracycline-class antibiotics against these resistant bacteria. ERV showed superior in vitro potency than TGC and OMC, with lower concentrations needed to inhibit bacterial growth. ERV also killed CRAB more effectively and for a longer duration than the other two antibiotics. In clinical settings, patients treated with ERV had a 5% mortality rate, compared with 18.9% for CRAB patients treated with TGC. Although limited by a small number of patients, the results suggest that ERV could be a promising treatment option for CRAB and CRKP infections, warranting further multi-center validation.
Keywords: carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Klebsiella pneumoniae, broth microdilution, time-kill assays, tetracycline-class antibiotics
1Department of Clinical Laboratory, Xuanwu Hospital Capital Medical University, National Gerontic Disease Clinical Research Center, Beijing, 100053, People’s Republic of China; 2Department of Clinical Laboratory, Xiong’an Xuanwu Hospital, Xiong’an New Area, Hebei Province, 070001, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jingrong Cao, Department of Clinical Laboratory, Xuanwu Hospital Capital Medical University, National Gerontic Disease Clinical Research Center, No. 45 Changchun Street, Xicheng District, Beijing, 100053, People’s Republic of China, Email 13683581168@126.com Peichang Wang, Department of Clinical Laboratory, Xuanwu Hospital Capital Medical University, National Gerontic Disease Clinical Research Center, No. 45 Changchun Street, Xicheng District, Beijing, 100053, People’s Republic of China, Email pcw1905@126.com
Purpose: Carbapenem-resistant Acinetobacter baumannii (CRAB) and Klebsiella pneumoniae (CRKP) pose a serious public health threat, underscoring the urgent need for novel therapeutic options. This study compared the in vitro antimicrobial activity and associated clinical outcomes of three tetracycline-class antibiotics—eravacycline (ERV), tigecycline (TGC), and omadacycline (OMC)—against regional carbapenem-resistant isolates.
Patients and Methods: A total of 106 CRKP and 117 CRAB non-duplicate clinical isolates were collected from Xuanwu Hospital (Beijing) between December 2024 and June 2025. Minimum inhibitory concentrations (MICs) were determined using broth microdilution (CLSI M07 guidelines). Time-kill assays (0– 48 h) were used to evaluate bactericidal activity, and clinical outcomes were analyzed in patients treated with TGC or ERV.
Results: ERV demonstrated superior in vitro activity: its MIC90 against CRKP (0.5 μg/mL) was 4-fold lower than TGC (2 μg/mL) and 8-fold lower than OMC (4 μg/mL). For CRAB, ERV’s MIC90 (0.25 μg/mL) was 4-fold lower than TGC (1 μg/mL). ERV maintained sustained bactericidal activity (≥ 3-log10 CFU/mL reduction) for 24– 36 h against CRAB— 2.3-fold longer than TGC and 3.1-fold longer than OMC. ERV-treated patients (n = 20) showed a 5% mortality rate (6.7% for CRAB and 0% for CRKP), compared with 18.9% (CRAB) and 16.7% (CRKP) in TGC-treated patients.
Conclusion: Current evidence indicates that ERV exhibits strong in vitro bactericidal activity and demonstrates more favorable clinical efficacy comparable to that of TGC against CRKP and CRAB infections, as observed in our retrospective clinical cohort.
Plain Language Summary: Faced with the increasing threat of CRAB and CRKP, this study evaluated effectiveness of three tetracycline-class antibiotics against these resistant bacteria. ERV showed superior in vitro potency than TGC and OMC, with lower concentrations needed to inhibit bacterial growth. ERV also killed CRAB more effectively and for a longer duration than the other two antibiotics. In clinical settings, patients treated with ERV had a 5% mortality rate, compared with 18.9% for CRAB patients treated with TGC. Although limited by a small number of patients, the results suggest that ERV could be a promising treatment option for CRAB and CRKP infections, warranting further multi-center validation.
Keywords: carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Klebsiella pneumoniae, broth microdilution, time-kill assays, tetracycline-class antibiotics